Technology Bundle ID: TAB-2488

Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets

Request More Info
Licensing Contact:
Primary Inventors: 
Sanjay Desai (NIAID)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Early-stage
  • Pre-clinical
  • In vitro data available
Institute or Center: 
NIAID

There are two related technologies, the first being small molecule inhibitors of the malarial plasmodial surface anion channel (PSAC) and the second being the PSAC protein itself as a vaccine candidate. The PSAC protein is produced by the malaria parasite within host erythrocytes and is crucial for mediating nutrient uptake. In vitro data show that the PSAC inhibitors are able to inhibit growth of malaria parasites, have high specificity, and low toxicity. Portions of the PSAC protein are found on the outer surface of infected host erythrocytes and the protein was recently shown to be encoded by the clag3 gene. This discovery opens the possibility of developing the PSAC protein as a potential vaccine candidate against malaria.

Applications:
  • Antimalarial drugs
  • Malaria vaccine
Advantages:
  • Novel target against malaria
  • Small molecule inhibitors of PSAC inhibit malarial parasite growth, have low toxicity, and high specificity
  • PSAC protein is exposed on the surface of the infected host erythrocytes, making it an attractive vaccine candidate

Patents

PCT Application PCT/US12/33072
Filed on 2012-04-11
US Application 17/115,317
Filed on 2020-12-08
US Application 61/474,583
Filed on 2011-04-12
US Pat 10,265,313

Issued 2019-04-23
US Pat 10,869,865

Issued 2020-12-22
US Pat 9,320,786

Issued 2016-04-26
US Pat 9,808,458

Issued 2017-11-07

Publications

Desai SA.
PMID 22432505
Nguitragool W, et al.
PMID 21620134
Pillai AD, et al.
PMID 20101003
Pillai AD, et al.
PMID 22949525

Updated

Oct 22, 2012

Data Source: 
tts